Drug-coated Balloons Versus Drug-eluting Stents for the Treatment of Femoropopliteal In-Stent Restenosis

NCT07277218 · tracked via the Priya Life Science China tracker

Sponsor

Chunshui He

Phase

Observational

Started

2027-01-01

Last updated

2026-11-02

Condition(s) studied

Femoropopliteal In-Stent Restenosis (ISR)

Investigational drug(s) / intervention(s)

Drug-Coated Balloon-First StrategyEluvia Drug-Eluting Stent-First Strategy

Drug-Coated Balloon-First Strategy: Physician-selected routine-care treatment with either IN.PACT Admiral or AcoArt Orchid 0.035 after lesion preparation. Device size and length are selected according to vessel anatomy and locally approved instructions for use. Protocol-defined focal bare-metal bailout stenting is permitted when clinically required for a suboptimal DCB result.

Eluvia Drug-Eluting Stent-First Strategy: Physician-selected routine-care treatment with the Eluvia Drug-Eluting Vascular Stent System after lesion preparation. Stent diameter and length are selected according to vessel anatomy and locally approved instructions for use.

Study summary

Femoropopliteal in-stent restenosis (ISR) remains an important cause of recurrent symptoms and repeat revascularization after lower-extremity endovascular treatment. Drug-coated balloons (DCBs) avoid an additional permanent metallic layer, whereas drug-eluting stents provide mechanical scaffolding with local antiproliferative drug delivery. Direct prospective comparative-effectiveness evidence in symptomatic femoropopliteal ISR remains limited.

DEFIER is a prospective, multicenter observational comparative-effectiveness cohort study enrolling up to 600 adults with symptomatic Rutherford category 2-5 femoropopliteal ISR. Treatment is selected by the treating physician as part of routine clinical care and is not assigned by the research protocol. After guidewire crossing and lesion preparation, patients for whom both strategies remain clinically feasible enter the primary comparative cohort. The DCB-first strategy uses IN.PACT Admiral or AcoArt Orchid 0.035, with protocol-defined focal bare-metal bailout stenting permitted when clinically required. The Eluvia-first strategy uses the Eluvia drug-eluting vascular stent.

Participants will be followed for 24 months. The primary outcome is the cumulative incidence of first clinically driven target lesion revascularization (CD-TLR) through 24 months. Comparative analyses will use a prespecified target-trial framework and propensity-score overlap weighting, with death and major target-limb amputation treated as competing events.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: Age \>18 years. Willing and able to provide written informed consent. Rutherford Clinical Category 2-5. Angiographically confirmed ≥50% stenosis or occlusion within a previously implanted superficial femoral or proximal popliteal artery stent more than 30 days after implantation. The target lesion is within the previously stented segment or extends no more than 3 cm proximally or distally beyond the prior stent. Total target lesion length ≤30 cm. At least one patent below-the-knee runoff vessel. Willing and able to complete follow-up through 24 months. After lesion preparation, both the DCB-first and Eluvia-first strategies remain clinically feasible. Exclusion Criteria: Pregnancy or lactation. Rutherford Clinical Category 0 or 6. Target lesion stenosis \<50%. Target lesion length \>30 cm. Severe calcification precluding endovascular treatment. Acute limb ischemia or acute thrombosis of the target limb. Untreated hemodynamically significant aorto-iliac inflow disease. Cerebrovascular accident within 60 days before the index procedure. Contraindication to required antiplatelet or anticoagulant therapy. Inability or unwillingness to provide informed consent. Life expectancy \<2 years or another factor making completion of follow-up unlikely. Persistent post-preparation anatomy that mandates one treatment strategy and therefore eliminates clinical equipoise.

Primary outcome measure(s)

Clinically-Driven Target Lesion Revascularization (CD-TLR) — 24 months post-procedure
Clinically driven target lesion revascularization (CD-TLR) is defined as repeat percutaneous or surgical revascularization of the target lesion, defined as the treated segment plus 5 mm proximally and distally, for ≥50% restenosis or occlusion accompanied by recurrent or worsening limb symptoms, Rutherford-category deterioration, ABI/TBI decline consistent with hemodynamic worsening, including an ABI decline ≥0.15 from the post-procedure reference when applicable, or failure or worsening of tissue loss in patients with chronic limb-threatening ischemia. Events will be independently adjudicated.

Trial sites (10)

Facility	City	Region
Xuanwu Hospital, Capital Medical University	Beijing	Beijing Municipality
Xiamen Cardiovascular Hospital of Xiamen University	Xiamen	Fujian
Hangzhou First People's Hospital	Hangzhou	Hangzhou
Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	Hubei
The Second Affiliated Hospital of Soochow University	Suzhou	Jiangsu
Qingdao Haici Hospital Affiliated to Qingdao University	Qingdao	Shandong
Renji Hospital, Shanghai Jiao Tong University School of Medicine	Shanghai	Shanghai Municipality
Zhongshan Hospital, Fudan University	Shanghai	Shanghai Municipality
Hospital of Chengdu University of Traditional Chinese Medicine	Chengdu	Sichuan
Huashan Hospital, Fudan University	Shanghai	Sichuan

More Chunshui He trials in China

Pain During Heat Treatment for Lower Extremity Varicose Veins: Radiofrequency vs. Microwave Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07277218 on ClinicalTrials.gov ↗ ← All trials in China